(3 Minutes Read)
Pharmaceutical giant Sothema, under the leadership of CEO Lamia Tazi, has finalized a strategic acquisition agreement to purchase 99.99% of the share capital of Soludia Maghreb, one of Morocco’s foremost players in the hemodialysis sector. The transaction, valued at nearly MAD 1 billion (approximately USD 100 million), marks a significant consolidation in the Moroccan pharmaceutical and medical treatment landscape.
The acquisition was carried out in collaboration with Soludia Maghreb’s long standing shareholders, namely Abdelaziz Razkaoui, the Cap Mezzanine III fund managed by CDG Invest Growth, and members of the Zine family. These investors have played key roles in Soludia’s growth and development since its establishment.
Founded in 1996, Soludia Maghreb has become a critical industrial force in Morocco’s healthcare sector, particularly in the domain of renal care and hemodialysis treatments. The company specializes in the production of vital medical products used in dialysis procedures, including powdered bicarbonate cartridges as well as liquid acid and bicarbonate solutions, all of which are essential for the proper functioning of hemodialysis machines and patient care.
In addition to its manufacturing operations, Soludia is active in the distribution of specialized pharmaceutical products in collaboration with various international pharmaceutical firms. The company also holds a 40% stake in Hidropura Maroc, a niche firm that provides installation and ongoing maintenance of acid generation plants and water treatment systems tailored for hemodialysis clinics and medical centers across Morocco.
According to financial projections for 2025, Soludia Maghreb is expected to generate a revenue of MAD 360 million (USD 36 million), with an adjusted EBITDA of MAD 90 million (USD 9 million) — figures that do not yet account for potential performance improvements or cost synergies post-acquisition.
Read Also:
https://trendsnafrica.com/egypt-and-morocco-join-forces-for-regional-biomanufacturing-hub/
This acquisition strengthens Sothema’s position in Morocco’s health sector and is aligned with its strategy of expanding its footprint in chronic disease management and specialized care services, with a particular focus on renal therapies and medical infrastructure.